Pharmacological and Pharmacokinetic Aspects of Functional Gastrointestinal Disorders

Gastroenterology

Volumn 130, Issue 5, 2006, Pages 1421-1434

  Camilleri, Michael ^a   Bueno, Lionel ^b   de Ponti, Fabrizio ^d   Fioramonti, Jean ^c   Lydiard, R Bruce ^e   Tack, Jan ^f  

^a Mayo Clinic   (United States)

^b Unité de Neurogastroentérologie INRA ^*

^c INSERM   (France)

^d UNIVERSITY OF BOLOGNA   (Italy)

^e MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

^f UNIVERSITY OF LEUVEN   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

1 ACETOXYMETHYL 3 [7 [[1 (N,N DIMETHYLCARBAMOYL) 6 (4 FLUOROPHENYL) 3 INDOLYL]CARBONYL] 1H,3H PYRROLO[1,2 C]THIAZOL 3 YL]PYRIDINIUM CHLORIDE; 17 METHYLNALTREXONE; ADRENERGIC RECEPTOR STIMULATING AGENT; ALOSETRON; ALVIMOPAN; ANGIOPEPTIN; APREPITANT; ASIMADOLINE; BUSPIRONE; CAPSAICIN; CILANSETRON; CISAPRIDE; DEXLOXIGLUMIDE; DOMPERIDONE; ERYTHROMYCIN; FEDOTOZINE; LOPERAMIDE; LOXIGLUMIDE; METOCLOPRAMIDE; NALOXONE; NEPADUTANT; OCTREOTIDE; PRUCALOPRIDE; RENZAPRIDE; SEROTONIN 4 AGONIST; SULPIRIDE; TACHYKININ RECEPTOR ANTAGONIST; TALNETANT; TEGASEROD; UNINDEXED DRUG;

ALLODYNIA; ARTICLE; CLINICAL TRIAL; CONSENSUS; DIGESTIVE SYSTEM FUNCTION DISORDER; DOCUMENTATION; DRUG SELECTIVITY; DYSPEPSIA; EVALUATION; HUMAN; HYPERALGESIA; INTESTINE MOTILITY; INTESTINE TRANSIT TIME; IRRITABLE COLON; ISCHEMIC COLITIS; NONHUMAN; PATHOPHYSIOLOGY; PRIORITY JOURNAL; SENSATION; STIMULUS; STOMACH EMPTYING; STOMACH PARESIS; TACHYCARDIA; VISCERAL PAIN;

EID: 33646179154     PISSN: 00165085     EISSN: None     Source Type: Journal    
DOI: 10.1053/j.gastro.2005.08.062     Document Type: Article

References (121)

1. Rouzade M.L., Fioramonti J., and Bueno L. A model for evaluation of gastric sensitivity in awake rats. Neurogastroenterol Motil 10 (1998) 157-163
2. Morteau O., Hachet T., Caussette M., and Bueno L. Experimental colitis alters visceromotor response to colorectal distension in awake rats. Dig Dis Sci 39 (1994) 1239-1248
3. Louvel D., Delvaux M., Staumont G., Camman F., Fioramonti J., Bueno L., and Frexinos J. Intracolonic injection of glycerol. a model for abdominal pain in irritable bowel syndrome?. Gastroenterology 110 (1996) 351-361
4. Woodsworth R.S., and Sherrington C.S. A pseudoaffective reflex and its spinal path. J Physiol 31 (1904) 234-243
5. Kamp E.H., Jones III R.C., Tillman S.R., and Gebhart G.F. Quantitative assessment and characterization of visceral nociception and hyperalgesia in mice. Am J Physiol 284 (2003) G434-G444
6. Ozaki N., Bielefeldt K., Sengupta J.N., and Gebhart G.F. Models of gastric hyperalgesia in the rat. Am J Physiol 283 (2002) G666-G676
7. Ness T.J., and Gebhart G.F. Colorectal distension as a noxious visceral stimulus. physiologic and pharmacologic characterization of pseudoaffective reflexes in the rat. Brain Res 450 (1988) 153-169
8. Su X., Julia V., and Gebhart G.F. Effects of intracolonic opioid receptor agonists on polymodal pelvic nerve afferent fibers in the rat. J Neurophysiol 83 (2000) 963-970
9. Booth C.E., Kirkup A.J., Hicks G.A., Humphrey P.P., and Grundy D. Somatostatin sst(2) receptor-mediated inhibition of mesenteric afferent nerves of the jejunum in the anesthetized rat. Gastroenterology 121 (2001) 358-369
10. Fioramonti J., Gaultier E., Toulouse M., Sanger G.J., and Bueno L. Intestinal anti-nociceptive behaviour of NK3 receptor antagonism in conscious rats. evidence to support a peripheral mechanism of action. Neurogastroenterol Motil 15 (2003) 363-369
11. McLean P.G., Picard C., Garcia-Villar R., More J., Fioramonti J., and Bueno L. Effects of nematode infection on sensitivity to intestinal distension. role of tachykinin NK2 receptors. Eur J Pharmacol 337 (1997) 279-282
12. Gue M., Rio-Lacheze C., Eutamene H., Theodorou V., Fioramonti J., and Bueno L. Stress-induced visceral hypersensitivity to rectal distension in rats. role of CRF and mast cells. Neurogastroenterol Motil 9 (1997) 271-279
13. Coelho A.M., Fioramonti J., and Bueno L. Systemic lipopolysaccharide influences rectal sensitivity in rats. role of mast cells, cytokines, and vagus nerve. Am J Physiol 279 (2000) G781-G790
14. Barreau F., Cartier C., Ferrier L., Fioramonti J., and Bueno L. Nerve growth factor mediates alterations of colonic sensitivity and mucosal barrier induced by neonatal stress in rats. Gastroenterology 127 (2004) 524-534
15. Al Chaer E.D., Kawasaki M., and Pasricha P.J. A new model of chronic visceral hypersensitivity in adult rats induced by colon irritation during postnatal development. Gastroenterology 119 (2000) 1276-1285
16. Gue M., Junien J.L., and Bueno L. The kappa agonist fedotozine modulates colonic distention-induced inhibition of gastric motility and emptying in dogs. Gastroenterology 107 (1994) 1327-1334
17. Tjeerdsma H.C., Smout A.J., and Akkermans L.M. Voluntary suppression of defecation delays gastric emptying. Dig Dis Sci 38 (1993) 832-836
18. Gue M., Peeters T., Depoortere I., Vantrappen G., and Bueno L. Stress-induced changes in gastric emptying, postprandial motility, and plasma gut hormone levels in dogs. Gastroenterology 97 (1989) 1101-1107
19. Williams C.L., Peterson J.M., Villar R.G., and Burks T.F. Corticotropin-releasing factor directly mediates colonic responses to stress. Am J Physiol 253 (1987) G582-G586
20. Briejer M.R., Veen G.J., Akkermans L.M., Lefebvre R.A., and Schuurkes J.A. Cisapride and structural analogs selectively enhance 5-hydroxytryptamine (5-HT)-induced purinergic neurotransmission in the guinea pig proximal colon. J Pharmacol ExpTher 274 (1995) 641-648
21. Tonini M., De Ponti F., Di Nucci A., and Crema F. Review article. cardiac adverse effects of gastrointestinal prokinetics. Aliment Pharmacol Ther 13 (1999) 1585-1591
22. Morphy R., Kay C., and Rankovic Z. From magic bullets to designed multiple ligands. Drug Discov Today 9 (2004) 641-651
23. Camilleri M., Northcutt A.R., Kong S., Dukes G.E., McSorley D., and Mangel A.W. Efficacy and safety of alosetron in women with irritable bowel syndrome. a randomised, placebo-controlled trial. Lancet 355 (2000) 1035-1040
24. Muller-Lissner S.A., Fumagalli I., Bardhan K.D., Pace F., Pecher E., Nault B., and Ruegg P. Tegaserod, a 5-HT4 receptor partial agonist, relieves symptoms in irritable bowel syndrome patients with abdominal pain, bloating and constipation. Aliment Pharmacol Ther 15 (2001) 1655-1666
25. Cremonini F., Delgado-Aros S., and Camilleri M. Efficacy of alosetron in irritable bowel syndrome. a meta-analysis of randomized controlled trials. Neurogastroenterol Motil 15 (2003) 79-86
26. Tonini M., Spelta V., De Ponti F., De Giorgio R., D'Agostino G., Stanghellini V., Corinaldesi R., Sternini C., and Crema F. Tachykinin-dependent and -independent components of peristalsis in the guinea pig isolated distal colon. Gastroenterology 120 (2001) 938-945
27. Holzer P. Tachykinin receptor antagonists. silencing neuropeptides with a role in the disturbed gut. In: Spiller R., and Grundy D. (Eds). Pathophysiology of the enteric nervous system (2004), Blackwell, London, England 212-227
28. De Ponti F. Methylnaltrexone progenics. Curr Opin Investig Drugs 3 (2002) 614-620
29. Holzer P. Opioids and opioid receptors in the enteric nervous system. from a problem in opioid analgesia to a possible new prokinetic therapy in humans. Neurosci Lett 361 (2004) 192-195
30. Bott C., Rudolph M.W., Schneider A.R., Schirrmacher S., Skalsky B., Petereit H.U., Langguth P., Dressman J.B., and Stein J. In vivo evaluation of a novel pH- and time-based multiunit colonic drug delivery system. Aliment Pharmacol Ther 20 (2004) 347-353
31. Nugent S.G., Kumar D., Rampton D.S., and Evans D.F. Intestinal luminal pH in inflammatory bowel disease. possible determinants and implications for therapy with aminosalicylates and other drugs. Gut 48 (2001) 571-577
32. De Ponti F., Poluzzi E., and Montanaro N. Organising evidence on QT prolongation and occurrence of torsades de pointes with non-antiarrhythmic drugs. a call for consensus. Eur J Clin Pharmacol 57 (2001) 185-209
33. Moynihan R. Alosetron. a case study in regulatory capture, or a victory for patients' rights?. BMJ 325 (2002) 592-595
34. De Ponti F., Poluzzi E., Cavalli A., Recanatini M., and Montanaro N. Safety of non-antiarrhythmic drugs that prolong the QT interval or induce torsade de pointes. an overview. Drug Saf 25 (2002) 263-286
35. Lembo A., and Camilleri M. Chronic constipation. N Engl J Med 349 (2003) 1360-1368
36. O'Mahony L, McCarthy J, Kelly P, Hurley G, Luo F, Chen K, O'Sullivan GC, Kiely B, Collins JK, Shanahan F, Quigley EMM. A randomized, placebo-controlled, double-blind comparison of the probiotic bacteria lactobacillus and bifidobacterium in irritable bowel syndrome (IBS): symptom responses and relationship to cytokine profiles. Gastroenterology (in press).
37. Lesbros-Pantoflickova D., Michetti P., Fried M., Beglinger C., and Blum A.L. Meta-analysis. the treatment of irritable bowel syndrome. Aliment Pharmacol Ther 20 (2004) 1253-1269
38. Gershon M.D., and Jonakait G.M. Uptake and release of 5-hydroxytryptamine by enteric 5-hydroxytryptaminergic neurones. effects of fluoxetine (Lilly 110140) and chlorimipramine. Br J Pharmacol 66 (1979) 7-9
39. Gorard D.A., Libby G.W., and Farthing M.J. 5-Hydroxytryptamine and human small intestinal motility. effect of inhibiting 5-hydroxytryptamine reuptake. Gut 35 (1994) 496-500
40. De Ponti F. Pharmacology of serotonin. what a clinician should know. Gut 53 (2004) 1520-1535
41. Talley N.J., Phillips S.F., Haddad A., Miller L.J., Twomey C., Zinsmeister A.R., MacCarty R.L., and Ciociola A. GR 38032F (ondansetron), a selective 5HT3 receptor antagonist, slows colonic transit in healthy man. Dig Dis Sci 35 (1990) 477-480
42. Gore S., Gilmore I.T., Haigh C.G., Brownless S.M., Stockdale H., and Morris A.I. Colonic transit in man is slowed by ondansetron (GR38032F), a selective 5-hydroxytryptamine receptor (type 3) antagonist. Aliment Pharmacol Ther 4 (1990) 139-144
43. Scolapio J.S., Camilleri M., der Ohe M.R., and Hanson R.B. Ascending colon response to feeding. evidence for a 5-hydroxytryptamine-3 mechanism. Scand J Gastroenterol 30 (1995) 562-567
44. Caras S., Krause G., Biesheuvel E., and Steinborn C. Cilansetron shows efficacy in male and female non-constipated patients with irritable bowel syndrome in a United States study (abstr). Gastroenterology 120 (2001) A217
45. Chey W.D., and Cash B.D. Cilansetron. a new serotonergic agent for the irritable bowel syndrome with diarrhoea. Expert Opin Investig Drugs 14 (2005) 185-193
46. Bouras E.P., Camilleri M., Burton D.D., and McKinzie S. Selective stimulation of colonic transit by the benzofuran 5HT4 agonist, prucalopride, in healthy humans. Gut 44 (1999) 682-686
47. Poen A.C., Felt-Bersma R.J., Van Dongen P.A., and Meuwissen S.G. Effect of prucalopride, a new enterokinetic agent, on gastrointestinal transit and anorectal function in healthy volunteers. Aliment Pharmacol Ther 13 (1999) 1493-1497
48. Degen L., Matzinger D., Merz M., Appel-Dingemanse S., Osborne S., Luchinger S., Bertold R., Maecke H., and Beglinger C. Tegaserod, a 5-HT4 receptor partial agonist, accelerates gastric emptying and gastrointestinal transit in healthy male subjects. Aliment Pharmacol Ther 15 (2001) 1745-1751
49. Tack J., Vos R., Janssens J., Salter J., Jauffret S., and Vandeplassche G. Influence of tegaserod on proximal gastric tone and on the perception of gastric distension. Aliment Pharmacol Ther 18 (2003) 1031-1037
50. Bouhassira D., Chollet R., Coffin B., Lemann M., Le Bars D., Willer J.C., and Jian R. Inhibition of a somatic nociceptive reflex by gastric distention in humans. Gastroenterology 107 (1994) 985-992
51. Coffin B., Farmachidi J.P., Rueegg P., Bastie A., and Bouhassira D. Tegaserod, a 5-HT4 receptor partial agonist, decreases sensitivity to rectal distension in healthy subjects. Aliment Pharmacol Ther 17 (2003) 577-585
52. Novick J., Miner P., Krause R., Glebas K., Bliesath H., Ligozio G., Ruegg P., and Lefkowitz M. A randomized, double-blind, placebo-controlled trial of tegaserod in female patients suffering from irritable bowel syndrome with constipation. Aliment Pharmacol Ther 16 (2002) 1877-1888
53. Kellow J., Lee O.Y., Chang F.Y., Thongsawat S., Mazlam M.Z., Yuen H., Gwee K.A., Bak Y.T., Jones J., and Wagner A. An Asia-Pacific, double blind, placebo controlled, randomised study to evaluate the efficacy, safety, and tolerability of tegaserod in patients with irritable bowel syndrome. Gut 52 (2003) 671-676
54. Emmanuel A.V., Roy A.J., Nicholls T.J., and Kamm M.A. Prucalopride, a systemic enterokinetic, for the treatment of constipation. Aliment Pharmacol Ther 16 (2002) 1347-1356
55. Johanson J.F., Wald A., Tougas G., Chey W.D., Novick J.S., Lembo A.J., Fordham F., Guella M., and Nault B. Effect of tegaserod in chronic constipation. a randomized, double-blind, controlled trial. Clin Gastroenterol Hepatol 2 (2004) 796-805
56. Galligan J.J., Surprenant A., Tonini M., and North R.A. Differential localization of 5-HT1 receptors on myenteric and submucosal neurons. Am J Physiol 255 (1988) G603-G611
57. Tack J., Van Elzen B., Tytgat G., Wajs E., Van Nueten L., De Ridder F., and Boeckxstaens G. A placebo-controlled trial of the 5-HT1A agonist R-137696 on symptoms, visceral hypersensitivity and on impaired accommodation in functional dyspepsia (abstr). Gastroenterology 126 Suppl 2 (2004) A70
58. Itoh Z. Motilin and clinical application. Peptides 18 (1997) 593-608
59. Bruley des Varannes S., Parys V., Ropert A., Chayvialle J.A., Roze C., and Galmiche J.P. Erythromycin enhances fasting and postprandial proximal gastric tone in humans. Gastroenterology 109 (1995) 32-39
60. Piessevaux H., Tack J., Wilmer A., Coulie B., Geubel A., and Janssens J. Perception of changes in wall tension of the proximal stomach in humans. Gut 49 (2001) 203-208
61. Annese V., Janssens J., Vantrappen G., Tack J., Peeters T.L., Willemse P., and Van Cutsem E. Erythromycin accelerates gastric emptying by inducing antral contractions and improved gastroduodenal coordination. Gastroenterology 102 (1992) 823-828
62. Verhagen M.A., Samsom M., Maes B., Geypens B.J., Ghoos Y.F., and Smout A.J. Effects of a new motilide, ABT-229, on gastric emptying and postprandial antroduodenal motility in healthy volunteers. Aliment Pharmacol Ther 11 (1997) 1077-1086
63. Maganti K., Onyemere K., and Jones M.P. Oral erythromycin and symptomatic relief of gastroparesis. a systematic review. Am J Gastroenterol 98 (2003) 259-263
64. Talley N.J., Verlinden M., Snape W., Beker J.A., Ducrotte P., Dettmer A., Brinkhoff H., Eaker E., Ohning G., Miner P.B., Mathias J.R., Fumagalli I., Staessen D., and Mack R.J. Failure of a motilin receptor agonist (ABT-229) to relieve the symptoms of functional dyspepsia in patients with and without delayed gastric emptying. a randomized double-blind placebo-controlled trial. Aliment Pharmacol Ther 14 (2000) 1653-1661
65. Bologna S.D., Hasler W.L., and Owyang C. Down-regulation of motilin receptors on rabbit colon myocytes by chronic oral erythromycin. J Pharmacol Exp Ther 266 (1993) 852-856
66. Lecci A., Capriati A., and Maggi C.A. Tachykinin NK2 receptor antagonists for the treatment of irritable bowel syndrome. Br J Pharmacol 141 (2004) 1249-1263
67. Bharucha A.E., Camilleri M., Zinsmeister A.R., and Hanson R.B. Adrenergic modulation of human colonic motor and sensory function. Am J Physiol 273 (1997) G997-G1006
68. Viramontes B.E., Malcolm A., Camilleri M., Szarka L.A., McKinzie S., Burton D.D., and Zinsmeister A.R. Effects of an a2-adrenergic agonist on gastrointestinal transit, colonic motility, and sensation in humans. Am J Physiol 281 (2001) G1468-G1476
69. Malcolm A., Camilleri M., Kost L., Burton D.D., Fett S.L., and Zinsmeister A.R. Towards identifying optimal doses for alpha-2 adrenergic modulation of colonic and rectal motor and sensory function. Aliment Pharmacol Ther 14 (2000) 783-793
70. Coffin B., Bouhassira D., Chollet R., Fraitag B., De Meynard C., Geneve J., Lemann M., Willer J.C., and Jian R. Effect of the kappa agonist fedotozine on perception of gastric distension in healthy humans. Aliment Pharmacol Ther 10 (1996) 919-925
71. Delvaux M., Louvel D., Lagier E., Scherrer B., Abitbol J.L., and Frexinos J. The k-agonist fedotozine relieves hypersensitivity to colonic distention in patients with irritable bowel syndrome. Gastroenterology 116 (1999) 38-45
72. Delvaux M., Jacob J., Beck A., Bouzamondo H., Weber F.T., and Frexinos J. Effect of asimadoline, a new agonist of kappa opiate receptors on pain induced by rectal distension in IBS patients. Gastroenterology 122 (2002) A221
73. Delgado-Aros S., Chial H.J., Camilleri M., Szarka L.A., Weber F.T., Jacob J., Ferber I., McKinzie S., Burton D.D., and Zinsmeister A.R. Effects of a kappa-opioid agonist, asimadoline, on satiation and GI motor and sensory functions in humans. Am J Physiol 284 (2003) G558-G566
74. Read N.W., Abitbol J.L., Bardhan K.D., Whorwell P.J., and Fraitag B. Efficacy and safety of the peripheral kappa agonist fedotozine versus placebo in the treatment of functional dyspepsia. Gut 41 (1997) 664-668
75. Dapoigny M., Abitbol J.L., and Fraitag B. Efficacy of peripheral kappa agonist fedotozine versus placebo in treatment of irritable bowel syndrome. a multicenter dose-response study. Dig Dis Sci 40 (1995) 2244-2248
76. Corazziari E. Role of opioid ligands in the irritable bowel syndrome. Can J Gastroenterol 13 Suppl A (1999) 71A-75A
77. Walsh J.H. Gastrointestinal hormones. Physiology of the gastrointestinal tract (1994), Raven, New York, NY 1-128
78. De Ponti F., and Malagelada J.R. Functional gut disorders: from motility to sensitivity disorders. A review of current and investigational drugs for their management. Pharmacol Ther 80 (1998) 49-88
79. Scarpignato C., and Pelosini I. Management of irritable bowel syndrome. novel approaches to the pharmacology of gut motility. Can J Gastroenterol 13 Suppl A (1999) 50A-65A
80. Chan C.L., Facer P., Davis J.B., Smith G.D., Egerton J., Bountra C., Williams N.S., and Anand P. Sensory fibres expressing capsaicin receptor TRPV1 in patients with rectal hypersensitivity and faecal urgency. Lancet 361 (2003) 385-391
81. Bortolotti M., Coccia G., Grossi G., and Miglioli M. The treatment of functional dyspepsia with red pepper. Aliment Pharmacol Ther 16 (2002) 1075-1082
82. Tonini M., Cipollina L., Poluzzi E., Crema F., Corazza G.R., and De Ponti F. Review article. clinical implications of enteric and central D2 receptor blockade by antidopaminergic gastrointestinal prokinetics. Aliment Pharmacol Ther 19 (2004) 379-390
83. Moayyedi P., Soo S., Deeks J., Delaney B., Innes M., and Forman D. Pharmacological interventions for non-ulcer dyspepsia. Cochrane Database Syst Rev (2004) CD001960
84. Veldhuyzen van Zanten S.J., Jones M.J., Verlinden M., and Talley N.J. Efficacy of cisapride and domperidone in functional (nonulcer) dyspepsia. a meta-analysis. Am J Gastroenterol 96 (2001) 689-696
85. Poynard T., Regimbeau C., and Benhamou Y. Meta-analysis of smooth muscle relaxants in the treatment of irritable bowel syndrome. Aliment Pharmacol Ther 15 (2001) 355-361
86. Plourde V., Lembo T., Shui Z., Parker J., Mertz H., Tache Y., Sytnik B., and Mayer E.A. Effects of the somatostatin analogue octreotide on rectal afferent nerves in human. Am J Physiol 265 (1993) G751
87. Hasler W.L., Soudah H.C., and Owyang C. A somatostatin analogue inhibits afferent pathways mediating perception of rectal distention. Gastroenterology 104 (1993) 1390-1397
88. Hasler W., Soudah H.C., and Owyang C. Somatostatin analog inhibits afferent response to rectal distention in diarrhea-predominant irritable bowel patients. J Pharmacol Exp Ther 268 (1994) 1206-1211
89. Frytak S., Moertel C.G., O'Fallon J.R., Rubin J., Creagan E.T., O'Connell M.J., Schutt A.J., and Schwartau N.W. Delta-9-tetrahydrocannabinol as an antiemetic for patients receiving cancer chemotherapy. A comparison with prochlorperazine and a placebo. Ann Intern Med 91 (1979) 825-830
90. McCallum R.W., Soykan I., Sridhar K.R., Ricci D.A., Lange R.C., and Plankey M.W. Delta-9-tetrahydrocannabinol delays the gastric emptying of solid food in humans. a double-blind, randomized study. Aliment Pharmacol Ther 13 (1999) 77-80
91. Van Gaal L.F., Rissanen A.M., Scheen A.J., Ziegler O., Rossner S., and RIO-Europe Study Group. Effects of the cannabinoid-1 receptor blocker rimonabant on weight reduction and cardiovascular risk factors in overweight patients. 1-year experience from the RIO-Europe study. Lancet 365 (2005) 1389-1397
92. Valenzano K.J., Tafesse L., Lee G., Harrison J.E., Boulet J.M., Gottshall S.L., Mark L., Pearson M.S., Miller W., Shan S., Rabadi L., Rotshteyn Y., Chaffer S.M., Turchin P.I., Elsemore D.A., Toth M., Koetzner L., and Whiteside G.T. Pharmacological and pharmacokinetic characterization of the cannabinoid receptor 2 agonist, GW405833, utilizing rodent models of acute and chronic pain, anxiety, ataxia and catalepsy. Neuropharmacology 48 (2005) 658-672
93. Cann P.A., Read N.W., and Holdsworth C.O. What is the benefit of coarse wheat bran in patients with irritable bowel syndrome?. Gut 25 (1984) 168-173
94. Cann P.A., Read N.W., Holdsworth C.D., and Barends D. Role of loperamide and placebo in management of irritable bowel syndrome. Dig Dis Sci 29 (1984) 239-247
95. von der Ohe M.R., Camilleri M., Kvols L.K., and Thomforde G.M. Motor dysfunction of the small bowel and colon in patients with the carcinoid syndrome and diarrhea. N Engl J Med 329 (1993) 1073-1078
96. Bradette M., Delvaux M., Staumont G., Fioramonti J., Bueno L., and Frexinos J. Octreotide increases thresholds of colonic visceral perception in IBS patients without modifying muscle tone. Dig Dis Sci 39 (1994) 1171-1178
97. Lembo T., Naliboff B.D., Matin K., Munakata J., Parker R.A., Gracely R.H., and Mayer E.A. Irritable bowel syndrome patients show altered sensitivity to exogenous opioids. Pain 87 (2000) 137-147
98. Sturm A., Holtmann G., Goebell H., and Gerken G. Prokinetics in patients with gastroparesis. a systematic analysis. Digestion 60 (1999) 422-427
99. Talley N.J., Verlinden M., Geenen D.J., Hogan R.B., Riff D., McCallum R.W., and Mack R.J. Effects of a motilin receptor agonist (ABT-229) on upper gastrointestinal symptoms in type 1 diabetes mellitus. a randomised, double blind, placebo controlled trial. Gut 49 (2001) 395-401
100. Cremonini F., Mullan B.P., Camilleri M., Burton D.D., and Rank M.R. Performance characteristics of scintigraphic transit measurements for studies of experimental therapies. Aliment Pharmacol Ther 16 (2002) 1781-1790
101. Chial H.J., Camilleri C., Delgado-Aros S., Burton D., Thomforde G., Ferber I., and Camilleri M. A nutrient drink test to assess maximum tolerated volume and postprandial symptoms. effects of gender, body mass index and age in health. Neurogastroenterol Motil 14 (2002) 249-253
102. Arts J., Caenepeel P., Verbeke K., and Tack J. Influence of erythromycin on gastric emptying and meal related symptoms in functional dyspepsia with delayed gastric emptying. Gut 54 (2005) 455-460
103. Simonian H.P., Maurer A.H., Knight L.C., Kantor S., Kontos D., Megalooikonomou V., Fisher R.S., and Parkman H.P. Simultaneous assessment of gastric accommodation and emptying. studies with liquid and solid meals. J Nucl Med 45 (2004) 1155-1160
104. Bouras E.P., Delgado-Aros S., Camilleri M., Castillo E.J., Burton D.D., Thomforde G.M., and Chial H.J. SPECT imaging of the stomach: comparison with barostat, and effects of sex, age, body mass index, and fundoplication. Single photon emission computed tomography. Gut 51 (2002) 781-786
105. Gonsalkorale W.M., Perrey C., Pravica V., Whorwell P.J., and Hutchinson I.V. Interleukin 10 genotypes in irritable bowel syndrome. evidence for an inflammatory component?. Gut 52 (2003) 91-93
106. Camilleri M. Is there a SERT-ain association with IBS?. Gut 53 (2004) 1396-1399
107. Holtmann G., Siffert W., Haag S., Mueller N., Langkafel M., Senf W., Zotz R., and Talley N.J. G-protein beta 3 subunit 825 CC genotype is associated with unexplained (functional) dyspepsia. Gastroenterology 126 (2004) 971-979
108. Dalen P., Dahl M.L., Ruiz M.L., Nordin J., and Bertilsson L. 10-Hydroxylation of nortriptyline in white persons with 0, 1, 2, 3, and 13 functional CYP2D6 genes. Clin Pharmacol Ther 63 (1998) 444-452
109. Glatt C.E., and Reus V.I. Pharmacogenetics of monoamine transporters. Pharmacogenomics 4 (2003) 583-596
110. Camilleri M., Atanasova E., Carlson P.J., Ahmad U., Kim H.J., Viramontes B.E., McKinzie S., and Urrutia R. Serotonin-transporter polymorphism pharmacogenetics in diarrhea-predominant irritable bowel syndrome. Gastroenterology 123 (2002) 425-432
111. Gilman A.G., Hardman J.G., and Limbird L.E. Goodman & Gilman's the pharmacological basis of therapeutics. 10th ed. (2001), McGraw-Hill, New York, NY
112. Drossman D.A., Camilleri M., Mayer E.A., and Whitehead W.E. AGA technical review on irritable bowel syndrome. Gastroenterology 123 (2002) 2108-2131
113. Jackson J.L., O'Malley P.G., Tomkins G., Balden E., Santoro J., and Kroenke K. Treatment of functional gastrointestinal disorders with anti-depressants. a meta-analysis. Am J Med 108 (2000) 65-72
114. Brandt L.J., Bjorkman D., Fennerty M.B., Locke G.R., Olden K., Peterson W., Quigley E., Schoenfeld P., Schuster M., and Talley N. Systematic review on the management of irritable bowel syndrome in North America. Am J Gastroenterol 97 Suppl (2002) S7-S26
115. Drossman D.A., Toner B.B., Whitehead W.E., Diamant N.E., Dalton C.B., Duncan S., Emmott S., Proffitt V., Akman D., Frusciante K., Le T., Meyer K., Bradshaw B., Mikula K., Morris C.B., Blackman C.J., Hu Y., Jia H., Li J.Z., Koch G.G., and Bangdiwala S.I. Cognitive-behavioral therapy versus education and desipramine versus placebo for moderate to severe functional bowel disorders. Gastroenterology 125 (2003) 19-31
116. Kuiken S.D., Tytgat G.N., and Boeckxstaens G.E. The selective serotonin reuptake inhibitor fluoxetine does not change rectal sensitivity and symptoms in patients with irritable bowel syndrome. a double blind, randomized, placebo-controlled study. Clin Gastroenterol Hepatol 1 (2003) 219-228
117. Campo J.V., Perel J., Lucas A., Bridge J., Ehmann M., Kalas C., Monk K., Axelson D., Birmaher B., Ryan N., Di Lorenzo C., and Brent D.A. Citalopram treatment of pediatric recurrent abdominal pain and comorbid internalizing disorders. an exploratory study. J Am Acad Child Adolesc Psychiatry 43 (2004) 1234-1242
118. Tabas G., Beaves M., Wang J., Friday P., Mardini H., and Arnold G. Paroxetine to treat irritable bowel syndrome not responding to high-fiber diet. a double-blind, placebo-controlled trial. Am J Gastroenterol 99 (2004) 914-920
119. Creed F., Fernandes L., Guthrie E., Palmer S., Ratcliffe J., Read N., Rigby C., Thompson D., and Tomenson B. The cost-effectiveness of psychotherapy and paroxetine for severe irritable bowel syndrome. Gastroenterology 124 (2003) 303-317
120. Masand P.S., Gupta S., Schwartz T.L., Kaplan D., Virk S., Hameed A., and Lockwood K. Does a preexisting anxiety disorder predict response to paroxetine in irritable bowel syndrome?. Psychosomatics 43 (2002) 451-455
121. Lydiard R.B. Irritable bowel syndrome, anxiety, and depression. what are the links?. J Clin Psychiatry 62 Suppl 8 (2001) 38-45